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DRV concentrations and viral load in CSF in patients on DRV/r 600/
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Introduction: Darunavir/r (DRV/r) is currently used at a dose of 800/100 mg once daily (OD) in a high proportion of patients.
Pharmacokinetic data suggest that 600/100 OD may be effective, reducing toxicity and cost. However, drug concentrations in
reservoirs such as cerebrospinal fluid (CSF) might not be adequate to inhibit viral replication. We aimed to evaluate
concentrations of DRV and HIV-1 viral load (VL) in CSF patients receiving DRV 600/100 mg OD.
Methods: DRV600 is an ongoing randomized open study comparing DRV/r 800/100 mg (DRV800) vs 600/100 mg (DRV600) OD
plus TDF/FTC or ABC/3TC in 100 virologically suppressed patients (eudraCT 2011-006272-39). Here we present the results of a
CSF sub-study. A lumbar puncture (LP) was performed in participating patients after at least six months of inclusion in the study,
2028 hours after a dose of DRV/r. VL (PCR, LOD 40 copies/mL) was determined in CSF and in plasma. DRV concentrations were
quantified in CSF by liquid chromatography mass spectrometry (LC/MS/MS) and in plasma using high-performance liquid
chromatography (HPLC).
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1 896 16.62 0.0120 B40 B40 600/100TDF/FTC
2 802 5.79 0.0080 B40 280 600/100TDF/FTC
3 326 7.14 0.0388 B40 B40 600/100TDF/FTC
4 1390 23.04 0.0165 B40 B40 600/100TDF/FTC
5 1957 10.56 0.0089 B40 B40 600/100TDF/FTC
6 3235 30.19 0.0074 B40 B40 600/100TDF/FTC
7 3742 17.54 0.0028 B40 B40 600/100TDF/FTC
8 2363 23.99 0.0076 B40 B40 600/100TDF/FTC
Median (DRV 600/
100 mg)
1674 17.08 0.0084 B40 B40
9 1890 11.42 0.0018 B40 B40 800/100ABC/3TC
10 1569 13.81 0.0147 B40 B40 800/100ABC/3TC
11 3910 32.98 0.0035 B40 B40 800/100ABC/3TC
12 1258 17.96 0.0262 B40 B40 800/100ABC/3TC
13 958 3.47 0.0173 B40 159 800/100TDF/FTC
14 1876 12.02 0.0030 B40 B40 800/100TDF/FTC
15 1845 12.65 0.0061 B40 B40 800/100TDF/FTC
16 1389 23.12 0.0217 B40 B40 800/100TDF/FTC
Median (DRV 800/
100 mg)
1707 13.23 0.0104 B40 B40
Abbreviations: VL: HIV-1 RNA viral load; CSF: Cerebrospinal fluid; DRV/r: Darunavir/r; ARV: Antiretroviral.
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Results: Sixteen patients were included (eight in each arm). All DRV600 patients and four out of eight DRV800 patients received
TDF/FTC, and the other four ABC/3TC. 75% were males, median (range) age was 48 (1771) years, CD4 cell count 532 cells/mL
(1901,394). Median total time on DRV/r was 30 (1157) months, and since the beginning of the study 8 (612) months in
DRV800 and 10 (712) months in DRV600 patients. LP was performed a median of 26 (2428) hours after the last DRV/rTVD
or KVX dose. In DRV600 patients the median DRV plasma levels were 1,674 (3263,742) ng/mL, CSF levels 17.08 (5.7930.19)
ng/mL and DRV CSF:plasma ratio 0.0084 (0.00280.0388), while in the DRV800 arm, median DRV plasma levels were 1,707
(9583,910) ng/mL, CSF levels 13.23 (3.4732.98) ng/mL and DRV CSF:plasma ratio 0.0104 (0.00180.0262). All patients had
VLB40 copies/mL in plasma and 14 patients VLB40 copies/mL in CSF. Two patients (1 in each arm, and taking TDF/FTC) had
detectable VL in CSF (280 and 159 c/mL). These patients had the lowest CSF DRV concentrations (5.47 and 3.47 ng/mL), with
plasma DRV concentrations of 802 and 958 ng/mL respectively.
Conclusions: CSF DRV concentrations and CSF VL were similar between patients receiving DRV/r 800/100 mg or 600/100 mg OD.
Low CSF DRV concentrations might be associated with viral escape in CNS. This may be taken into account in patients receiving
OD DRV/r. Larger studies should confirm these findings.
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